Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Instem upbeat on outlook as it updates on 2016 progress

The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.
Instem upbeat on outlook as it updates on 2016 progress
The company's software is used to collate data from clinical trials

Instem Plc (LON:INS), developer and vendor of software used to log clinical trials, said it has started the new year in good heart after providing some granularity on its performance in 2016.

Already-flagged-up contract delays and the “disappointing performance” of Instem Clinical offset the strong performance of the bulk of the business.

The company’s investment in a product that complies with the US Food & Drug Administration’s Standard for Exchange of Nonclinical Data, or SEND protocol, appears well-judged.

In all it won 30 SEND-related contracts for its software – which makes it a leader in this field.

For the 12 months to December 31, revenues increased 11% to £18.1mln, Instem said, giving EBITDA of £1.2mln. Cash at the year-end was £4.4mln.

"Although the slowdown in the early phase clinical market and contract delays were disappointing, other parts of the business continued to perform well and we made significant progress during the year,” said chief executive Phil Reason. 

“Importantly, the overall market dynamics for our products and services remains positive and we therefore look forward to the next financial year with increasing optimism."

Ian_55ae0ddd437b7.jpg
Why Invest In Instem Plc? Read More Here

Register here to be notified of future INS Company articles
View full INS profile

Instem Plc Timeline

Big Picture
September 19 2016

Related Articles

BOSGLOBAL.jpg
December 21 2016
BOS spies a huge opportunity for 360 and so will focus all its efforts and financial firepower on the product.
financialGeneric-(Resized).png
March 02 2017
Customers of the creator of electronic trading platforms love a lot of volatility but its shareholders would probably appreciate a bit less.
Man on his phone
August 25 2016
Zamano's software is designed to assist companies with targeted, interactive, measurable online and mobile marketing campaigns.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use